BACKGROUND: Activated V gamma 9 V delta 2 T cells are able to kill most tumour cells because of recognition by T cell receptor and natural killer receptors. OBJECTIVE: We discuss the possibility that the intentional activation of gammadelta T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in cancer patients. METHODS: The antitumoral effects of gammadelta T cells both in vitro and in vivo have been demonstrated suggesting a new therapeutic approach for translation into the clinical setting. RESULTS/CONCLUSION: V gamma 9 V delta 2 T lymphocytes represent a particularly interesting target for immunotherapeutic protocols based on N- aminobisphosphonate administration and several Phase I-II trials are ongoing investigating the activity of zoledronic acid plus IL-2 in solid tumours.
CACCAMO, N.R., MERAVIGLIA, S., SCARPA, F., LA MENDOLA, C., SANTINI, D., BONANNO, C.T., et al. (2008). Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: doubts no more. EXPERT OPINION ON BIOLOGICAL THERAPY, 8(7), 875-883 [10.1517/14712598.8.7.875].
Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: doubts no more.
CACCAMO, Nadia Rosalia;MERAVIGLIA, Serena;SCARPA, Francesco;LA MENDOLA, Carmela;BONANNO, Cesira;MISIANO, Gabriella;DIELI, Francesco;SALERNO, Alfredo
2008-01-01
Abstract
BACKGROUND: Activated V gamma 9 V delta 2 T cells are able to kill most tumour cells because of recognition by T cell receptor and natural killer receptors. OBJECTIVE: We discuss the possibility that the intentional activation of gammadelta T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in cancer patients. METHODS: The antitumoral effects of gammadelta T cells both in vitro and in vivo have been demonstrated suggesting a new therapeutic approach for translation into the clinical setting. RESULTS/CONCLUSION: V gamma 9 V delta 2 T lymphocytes represent a particularly interesting target for immunotherapeutic protocols based on N- aminobisphosphonate administration and several Phase I-II trials are ongoing investigating the activity of zoledronic acid plus IL-2 in solid tumours.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
